Active substanceVancomycinVancomycin
Similar drugsTo uncover
  • Vancomobol®
    lyophilizate d / infusion 
    PREBAND PFC, LLC     Russia
  • Vancomycin
    powder d / infusion 
    KRASFARMA, JSC     Russia
  • Vancomycin
    powder d / infusion 
    FARMGID CJSC     Russia
  • Vancomycin
    lyophilizate inwards d / infusion 
  • Vancomycin
    lyophilizate inwards d / infusion 
    KRASFARMA, JSC     Russia
  • Vancomycin J
    lyophilizate d / infusion 
    JODAS EKSPOIM, LLC     Russia
  • Vancomycin-Teva
    lyophilizate d / infusion 
  • Vancoros®
    lyophilizate d / infusion 
    SYNTHESIS, OJSC     Russia
  • Vancocin®
    lyophilizate d / infusion 
    Eli Lilly East SA     Switzerland
  • Vero-Vancomycin
    lyophilizate d / infusion 
    VEROPHARM SA     Russia
  • Edicyin®
    lyophilizate d / infusion 
    Lek dd     Slovenia
  • Dosage form: & nbsplyophilizate for solution for infusion
    Composition:

    1 bottle of 500 mg or 1000 mg contains:

    active substance: vancomycin (in the form of vancomycin hydrochloride *) 500,000 ME (500 mg) or 1,000,000 ME (1000 mg);

    Excipients: hydrochloric acid to pH (3.2-3.3), sodium hydroxide to pH (3.2-3.3).

    * The activity of the substance of vancomycin hydrochloride is not less than 1050 IU / mg in terms of dry matter.

    Note

    The technological solvent - water for injections (500 mg dosage - up to 4 ml, dosage 1000 mg - up to 8 ml) is removed during lyophilization.

    Description:

    Almost white or white with a pinkish or light brown hue of color lyophilized mass.

    Pharmacotherapeutic group:Antibiotic glycopeptide
    ATX: & nbsp

    J.01.X.A.01   Vancomycin

    J.01.X.A   Antibiotics of the glycopeptide structure

    Pharmacodynamics:

    Vancomycin is a tricyclic glycopeptide antibiotic isolated from Amycolatopsis orientalis. The bactericidal action of vancomycin is manifested by inhibition of the cell wall biosynthesis. Besides, vancomycin changes the permeability of the bacterial cell membrane and the synthesis of RNA.

    Vancomycin is active against gram-positive microorganisms, such as Staphylococcus spp., in t.ch. Staphylococcus epidermidis and Staphylococcus aureus (including heterogeneous methicillin-resistant strains); Streptococcus spp., in t.ch. Streptococcus pyogenes, Streptococcus agalactiae, Enterococcus faecalis (formerly as Streptococcus faecalis), Streptococcus bovis, Streptococcus spp. groups viridans, Streptococcus pneumoniae (including penicillin-resistant strains); Clostridium spp., in t.ch. Clostridium difficile; Corynebacterium spp. Other microorganisms that are sensitive to vancomycin are Listeria monocytogenes, Lactobacillus spp., Actinomyces spp. and Bacillus spp.

    Vancomycin is inactive in vitro in relation to gram-negative microorganisms, Mycobacterium spp. and mushrooms.

    When applied orally does not have a systemic effect, acts locally on the sensitive microflora in the gastrointestinal tract (Staphylococcus aureus, Clostridium difficile).

    Pharmacokinetics:

    In individuals with normal renal function, repeated intravenous (iv) administration of 1 g of vancomycin (15 mg / kg) (infusion over 60 minutes) creates average plasma concentrations of about 63 mg / L immediately after completion of the infusion; 2 hours after the infusion, the average plasma concentrations were about 23 mg / L, and 11 hours after the infusion, about 8 mg / L. Multiple infusions of 500 mg administered over 30 minutes create mean plasma concentrations of about 49 mg / L after completion of the infusion; 2 hours after the infusion, the average plasma concentrations were about 19 mg / L, and after 6 hours, about 10 mg / L. Concentrations in blood plasma with repeated administration are similar to those in blood plasma with a single administration.

    Mean half-life (T1/2) of vancomycin from plasma is 4-6 hours in adult patients with normal renal function. In newborns T1/2 - 6-10 hours, infants - 4 hours, children over 1 year - 2-3 hours. About 75% of the administered dose of vancomycin is excreted by the kidneys due to the glomerular filtration within 24 hours. The average plasma clearance is about 0.058 l / kg / h, and the average renal clearance is about 0.048 l / kg / h. Renal clearance of vancomycin is quite constant and ensures its elimination by 70-80%.The volume of distribution varies from 0.3 to 0.43 l / kg. Vancomycin practically not metabolized. At a concentration of vancomycin in the serum from 10 mg / l to 100 mg / l, 55% of vancomycin is found in a protein-related condition. In small amounts it is excreted with bile.

    After iv introduction vancomycin is found in pleural, pericardial, synovial fluids, atrial auricle tissue, as well as in urine and in peritoneal fluid in concentrations that inhibit the growth of microorganisms. Vancomycin slowly and insignificantly penetrates the blood-brain barrier in normal, but with meningitis, its concentration in the CSF reaches bactericidal values. Vancomycin penetrates the placental barrier and into breast milk.

    Impaired renal function slows the excretion of vancomycin. In patients with missing kidneys, the mean T1/2 is 7.5 days, with chronic renal failure - 6-10 days. The total systemic and renal clearance of vancomycin can be reduced in elderly patients as a result of natural slowing of glomerular filtration.

    Poorly absorbed when ingested and usually does not enter the systemic circulation.Determined plasma concentrations of vancomycin may be noted in individual cases with repeated use of the inside of patients with acute pseudomembranous colitis caused by Clostridium difficile.

    Indications:

    For intravenous infusion

    Infectious-inflammatory diseases caused by microorganisms sensitive to vancomycin, including patients who are allergic to penicillins, cephalosporins; if there is no result of treatment with other antibiotics, including penicillins and cephalosporins; Vancomycin-sensitive microorganisms resistant to other antibiotics:

    - enondocarditis (endocarditis caused by Streptococcus spp. groups viridans, Streptococcus bovis (monotherapy, combination therapy with aminoglycosides); endocarditis caused by Enterococcus spp. (incl. Eterococcus faecalis; as a combination therapy with aminoglycosides); early endocarditis caused by Staphylococcus epidermidis or diphtheroids, after valve replacement (in combination with rifampicin, aminoglycosides / both antibiotics);

    - fromepsis;

    - andinfection of bones and joints;

    - andlower respiratory tract infections (pneumonia, lung abscess);

    - andskin and soft tissue infections;

    - andcentral nervous system (meningitis) infections.

    For oral administration

    - PSeventomembranous colitis associated with Clostridium difficile;

    - Staphylococcal enterocolitis.
    Contraindications:

    Hypersensitivity to vancomycin and other components of the drug, neuritis of the auditory nerve.

    Carefully:

    Hearing impairment (including history), renal failure (due to the possible development of ototoxic and nephrotoxic effects), patients with allergies to teicoplanin (the possibility of cross-allergy).

    Pregnancy and lactation:

    There is insufficient data on the safety of vancomycin in pregnancy. Evaluation of the results of experimental animal studies did not reveal the effect of vancomycin on the development of the embryo, fetus and the course of pregnancy.

    In controlled clinical trials vancomycin injected into / in pregnant women with severe staphylococcal infection. Vancomycin was found in the umbilical cord blood. No cases of sensorineural hearing loss or nephrotoxicity associated with vancomycin have been observed. One girl whose mother received vancomycin in the third trimester of pregnancy, suffered conductive hearing loss, which was not associated with the use of vancomycin.Since the number of patients in this study was limited and vancomycin were administered to women only in the second and third trimester of pregnancy, there was no precise data on the effect of vancomycin on the fetus.

    The drug Vancomycin-Teva should be used during pregnancy only in case of emergency, under the control of the concentration of vancomycin in the blood, in order to minimize the risk of toxic effects of vancomycin on the fetus.

    Vancomycin is excreted in breast milk. If you need to use the drug Vancomycin-Teva during lactation should stop breastfeeding.

    Dosing and Administration:

    For IV infusion and oral administration. Do not administer intramuscularly (IM).

    For intravenous infusion

    The rate of administration is not more than 10 mg / min. Duration of administration for at least 60 minutes. The recommended concentration is not more than 5 mg / ml. Patients who are shown to restrict fluid intake can use a concentration of up to 10 mg / ml and a rate of administration not exceeding 10 mg / min. However, if such concentrations are used, the incidence of side effects associated with infusion increases.

    Adults and children over 12 years (with normal renal function)

    For 500 mg every 6 hours or 1 g every 12 hours. The maximum daily dose is 2 g.

    Children over the age of 1 month and up to 12 years of age

    At 10 mg / kg IV every 6 hours. Each dose should be administered for at least 60 minutes. The maximum daily dose for a child should not be higher than the daily dose for an adult (2 g).

    Children under the age of 1 month

    The initial dose is 15 mg / kg, followed by 10 mg / kg every 12 hours during the first week of life and every 8 hours between the ages of 2 weeks and one month. Each dose should be administered for at least 60 minutes. In such patients, it is advisable to carefully monitor the concentration of vancomycin in the blood plasma.

    Recommendations for dosing vancomycin in neonates are given in Table 1.

    Table №1. Recommendations for dosing of vancomycin in newborns

    VNSBa

    (weeks)

    Chronological age (days)

    Serum creatinine (mg / dL)b

    Dose (mg / kg)

    less than 30

    not more than 7

    -c

    15 every 24 hours


    more than 7

    no more than 1,2

    10 every 12 hours

    30-36

    not more than 14

    -c

    10 every 12 hours


    more than 14

    not more than 0,6

    10 every 8 hours



    0,7-1,2

    10 every 12 hours

    more than 36

    not more than 7

    -c

    10 every 12 hours


    more than 7

    not more than 0,6

    10 every 8 hours



    0,7-1,2

    10 every 12 hours

    a - VMNB = age from the moment of the beginning of pregnancy (the age of intrauterine development plus the chronological age).

    b - if the serum creatinine concentration is more than 1.2 mg / dl, an initial dose of 15 mg / kg every 24 hours is used.

    from - serum creatinine concentration is not used to determine the dose for these patients, since this indicator is not informative in this case or due to lack of information.

    In such patients, it is advisable to carefully monitor the concentration of vancomycin in the blood serum.

    Patients with impaired renal function and elderly patients

    Patients with impaired renal function need to individually select the dose in accordance with the clearance of creatinine (CC). The dose is calculated using Table No. 2.

    In elderly patients vancomycin has a lower ground clearance and a larger volume of distribution. In this group, the choice of a dose is expedient to be carried out on the basis of the concentrations of vancomycin in the blood serum.

    In premature infants and in elderly patients, as a result of reduced renal function, a significant dose reduction may be required. The concentration of vancomycin in the blood plasma should be monitored regularly. In the table below, doses of vancomycin are given depending on the QC.

    Table number 2. Doses of vancomycin for patients with impaired renal function

    CK, ml / min

    Dose of vancomycin, mg / 24 h

    100

    1545

    90

    1390

    80

    1235

    70

    1080

    60

    925

    50

    770

    40

    620

    30

    465

    20

    310

    10

    155

    Patients with anuria treatment is started with a dose of 15 mg / kg body weight to quickly create therapeutic concentrations of vancomycin in the blood plasma. The dose required to maintain a stable concentration of vancomycin is 1.9 mg / kg / 24 hours. The recommended dose is 1 g for 7-10 days.

    Patients with severe renal insufficiency it is advisable to administer maintenance doses of 250-1000 mg once every few days.

    The QC can be calculated from the formulas:

    KK for men = body weight (kg) * (140 - age (full years)) / 72 * serum creatinine concentration;

    QC for women = QC men * 0.85.

    Preparation of solution for intravenous administration

    10 ml are added to the contents of the Vancomycin-Teva 500 mg bottle, and the contents of the Vancomycin-Teva Vial of 1000 mg are 20 ml of distilled water for injection to obtain a reconstituted solution of vancomycin at a concentration of 50 mg / ml. The reconstituted solution must be clear and free from foreign particles.

    The reconstituted solution can be stored at a temperature of not more than + 25 ° C for 24 hours or at a temperature of +2 + 8 ° C for 96 hours.

    Before infusion, further dilution of the aqueous solution is required.

    A reconstituted solution of Vancomycin-Teva 10 ml (or 20 ml) is added to 100 ml (or 200 ml) of 5% dextrose solution or 0.9% sodium chloride solution to obtain a solution of vancomycin for infusions at a concentration of 5 mg / ml. The prepared solution should be clear and free from foreign particles.

    The prepared solution of the drug Vancomycin-Teva for intravenous infusion can be stored at a temperature of no more than +25 ° C for 24 hours or at a temperature of + 2- + 8 ° C for 96 hours. From a microbiological point of view, drug solutions must be applied immediately after dilution if recovery and dilution occurred in controlled and standard aseptic conditions. If solutions are not used immediately after preparation, the terms and conditions of storage are the responsibility of the user.

    Before the infusion, the prepared intravenous solution should be visually inspected for mechanical impurities and discoloration. Solution for infusion is used after warming up to body temperature.

    For oral administration

    Vancomycin can be used orally to treat pseudomembranous colitis associated with Clostridium difficile, arisen after antibiotic therapy, and staphylococcal enterocolitis. In / in the introduction of vancomycin has no advantage in the treatment of pseudomembranous colitis and staphylococcal enterocolitis. Vancomycin Ineffective if ingested in the case of other infections.

    Adults

    2000 mg divided into 3-4 doses per day. The maximum daily dose of 2000 mg / day. The duration of treatment is 7-10 days.

    Children

    40 mg / kg divided into 3-4 doses per day. The maximum daily dose of 2000 mg / day. The duration of treatment is 7-10 days.

    Preparation of solution for ingestion

    The contents of the vial (500 mg of vancomycin) are diluted with 30 ml of water. The prepared solution can be taken or injected orally through a nasogastric tube. To improve the taste of the solution, ordinary food syrups can be added to it.

    Side effects:

    From the immune system: anaphylactoid reaction, drug rash, accompanied by eosinophilia and systemic manifestations.

    From the side of the cardiovascular system: cardiac arrest, "hot flashes" of blood, lowering of blood pressure (BP), shock (these symptoms are mainly associated with rapid infusion of the drug).

    From the digestive system: nausea, pseudomembranous colitis, increased activity of "liver" transaminases.

    From the side of the blood and lymphatic system: agranulocytosis, eosinophilia, reversible neutropenia, thrombocytopenia, pancytopenia, anemia, and leukopenia.

    From the side of the kidneys and urinary tract: interstitial nephritis, changes in functional renal tests, impaired renal function.

    From the skin and subcutaneous tissues: exfoliative dermatitis, benign (IgA) bladder dermatosis, itching dermatosis, rash, "red man" syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, hives, vasculitis.

    From the sense organs: ototoxic effects.

    In a number of patients who received vancomycin, such symptoms of ototoxicity as tinnitus, dizziness and hearing loss were observed. They can be transient or permanent. The majority of such cases were observed in patients receiving excessive doses of vancomycin, with a history of hearing loss or in patients receiving simultaneous treatment with other drugs with the possible development of ototoxicity, for example, aminoglycosides.

    Other: chills, drug fever, tissue necrosis at injection sites, pain at injection sites, thrombophlebitis.

    During or soon after too rapid infusion of vancomycin, patients may develop anaphylactoid reactions. Rapid administration of the drug can also cause the syndrome of "red man" (reddening of the upper body or pain and spasm of the muscles of the chest and back). After cessation of the infusion, these reactions usually take place within 20 minutes, but sometimes can last up to several hours.

    Overdose:

    Symptoms: increased severity of dose-dependent side effects.

    Treatment: symptomatic therapy. It is recommended to administer the liquid and monitor the plasma concentrations of vancomycin. Vancomycin poorly removed during dialysis. Hemofiltration and hemoperfusion through polysulfone ion exchange resin lead to an increase in vancomycin clearance.

    Interaction:

    With simultaneous intravenous administration of vancomycin and anesthetics, the appearance of erythema, histamine-like reddening of the skin and anaphylactoid reactions, and possibly lowering blood pressure or the development of neuromuscular blockade.The administration of vancomycin in the form of a 60-minute infusion prior to administration of an anesthetic may reduce the likelihood of these reactions occurring.

    Cross-resistance between vancomycin and antibiotics of other classes is absent. Cross-resistance between vancomycin and other glycopeptides is possible (teicoplanin).

    With simultaneous and / or sequential systemic or topical application of other potentially ototoxic and / or nephrotoxic drugs (aminoglycosides, amphotericin B, aminosalicylic acid or other salicylates, bacitracin. capreomycin, carmustine, paromomycin, ciclosporin, "loop" diuretics, polymyxin AT, cisplatin, ethacrynic acid) requires careful monitoring of the possible development of symptoms of ototoxicity (tinnitus, dizziness and hearing loss) and nephrotoxicity (increase in the concentration of creatinine and urea in the blood plasma, hematuria, proteinuria, rash, eosinophilia and eosinofiuria).

    Vancomycin acts synergistically with aminoglycosides, beta-lactams and rifampicin on sensitive microorganisms.

    Kolestyramin reduces the activity of vancomycin when it is ingested.

    Antihistamines, meclozine, phenothiazines, thioxanthenes can mask the symptoms of the ototoxic action of vancomycin (tinnitus, vertigo).

    The solution of vancomycin has a low pH, which can cause physical or chemical instability when mixed with other solutions. Avoid mixing with alkaline solutions.

    Solutions of vancomycin and beta-lactam antibiotics are physically incompatible when mixed. The probability of precipitation increases with increasing concentration of vancomycin. It is necessary to thoroughly wash the infusion system between the applications of these antibiotics. In addition, it is recommended to reduce the concentration of vancomycin to 5 mg / ml or less.

    Special instructions:

    The drug Vancomycin-Teva should be administered as a diluted solution for at least 60 minutes to avoid adverse reactions associated with infusion. Rapid administration (eg, within a few minutes) of vancomycin may be accompanied by a marked decrease in blood pressure and in rare cases, cardiac arrest. The cessation of infusion quickly leads to a reduction in infusion reactions.

    Patients receiving IV drug Vancomycin-Teva should be periodically analyzed the peripheral blood picture and monitoring the kidney function.

    Vancomycin-Teva should be used with caution in patients with renal insufficiency and elderly patients older than 60 years, since high, long-term concentrations of vancomycin in the blood plasma may increase the risk of toxic effects of the drug (maximum concentrations should not exceed 40 μg / ml, and minimal - 10 mcg / ml, concentrations above 80 mcg / ml are considered toxic). For patients with renal insufficiency, the doses of the drug should be selected individually.

    When using the drug Vancomycin-Teva, there may be signs of ototoxicity, both temporary and permanent. Usually ototoxicity is observed in patients receiving high doses of the drug, as well as in patients with hearing loss or with the simultaneous use of other ototoxic drugs. With concomitant renal failure, the risk of vancomycin toxicity increases. The incidence and severity of thrombophlebitis can be reduced by properly diluting the original solution and alternating the injection site.The drug Vancomycin-Teva is contraindicated to inject in / m due to the development of necrosis at the injection site.

    Before the introduction of the drug, it is necessary to establish the sensitivity of microorganisms to vancomycin. Long-term use of vancomycin can lead to the emergence of resistant strains of bacteria and the development of superinfection. Single cases of pseudomembranous colitis with intravenous vancomycin were described.

    Effect on the ability to drive transp. cf. and fur:

    Care should be taken with the use of the drug Vancomycin-Teva due to the fact that it is possible to develop dizziness, which can affect the ability to drive vehicles and mechanisms.

    Form release / dosage:

    Lyophilizate for the preparation of a solution for infusions, 500 mg or 1000 mg.

    Packaging:

    500 mg or 1000 mg of active substance into a clear glass bottle (type I) sealed with a rubber stopper and crimped with an aluminum cap with an upper plastic insert.

    1 bottle with instructions for use in a cardboard box.

    Storage conditions:

    Store at a temperature of 15 to 25 ° C, in a place protected from light.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:П N014771 / 01
    Date of registration:10.12.2008 / 25.07.2014
    Expiration Date:Unlimited
    The owner of the registration certificate:Teva Pharmaceutical Enterprises Co., Ltd.Teva Pharmaceutical Enterprises Co., Ltd. Israel
    Manufacturer: & nbsp
    Representation: & nbspTeva Teva Israel
    Information update date: & nbsp22.01.2017
    Illustrated instructions
      Instructions
      Up